459
Views
0
CrossRef citations to date
0
Altmetric
Research Report

Polymorphisms of the ABCB1 Gene are Associated with the Therapeutic Response to Risperidone in Chinese Schizophrenia Patients

, , , , , , , , & show all
Pages 987-993 | Published online: 20 Oct 2006

Bibliography

  • Kim RB , FrommMF, Wandel Cet al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest.101 , 289–294 (1998).
  • Uhr M , GrauerMT: abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.J. Psychiatr Res.37 , 179–185 (2003).
  • Wang JS , TaylorR, RunY, DonovanLJ, MarkowitzSJ, DeVaneCL: Olanzapine penetration into brain is greater in transgenic mdr1a P-glycoprotein deficient mice than FVB1 (wild-type) animals.Neuropsychopharmacology29 , 551–557 (2004).
  • Wang JS , DeVaneCL, GibsonBB, DonovanJL, MarkowitzJS, ZhuHJ: Population pharmacokinetic analysis of drug–drug interactions among risperidone, bupropion, and sertraline in CF1 mice.Psychopharmacology (Berl)183(4) , 490–499 (2006).
  • Yasui-Furukori N , SaitoM, NakagamiT, KanedaA, TateishiT, KanekoS: Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.Prog. Neuropsychopharmacol Biol. Psychiatry30(2) , 286–291 (2006).
  • Peuskens J : Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.Br. J. Psychiatry166(6) , 712–726 (1995).
  • Heck AH , HaffmansPM, de Groot IW, Hoencamp E: Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr. Res.46(2–3) , 97–105 (2000).
  • Csernansky JG , MahmoudR, Brenner R; Risperidone-USA-79 Study Group: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med346(1) , 16–22 (2002).
  • Freudenreich O , GoffDC: Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.Acta Psychiatr. Scand.106(5) , 323–330 (2002).
  • Boulton DW , DeVaneCL, ListonHL, MarkowitzJS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.Life Sci.71(2) , 163–169 (2002).
  • Ejsing TB , PedersenAD, LinnetK: P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug–drug interaction experiments.Hum. Psychopharmacol.20(7) , 493–500 (2005).
  • Wang JS , RuanY, TaylorRM, DonovanJL, MarkowitzJS, DeVaneCL: The brain entry of risperidone and 9-OH-risperidone is greatly limited by P-glycoprotein.Int. J. Neuropsychopharmacol7(4) , 415–419 (2004).
  • Fojo A , LeboR, ShimizuN et al.: Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat. Cell Mol. Genet.12(4) , 415–420 (1986).
  • Hoffmeyer S , BurkO, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7) , 3473–3478 (2000).
  • Kerb R , HoffmeyerS, BrinkmannU: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.Pharmacogenomics2(1) , 51–64 (2001).
  • Furuno T , LandiMT, CeroniM et al.: Expression polymorphism of the blood–brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics12(7) , 529–534 (2002).
  • Wang D , JohnsonAD, PappAC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics.15(10) , 693–704 (2005).
  • Drozdzik M , BialeckaM, MysliwiecK, HonczarenkoK, StankiewiczJ, SychZ: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease.Pharmacogenetics13(5) , 259–263 (2003).
  • Jones PM , GeorgeAM: A new structural model for P-glycoprotein.J. Membr. Biol.166(2) , 133–147 (1998).
  • Kim RB , LeakeBF, ChooEF et al.: Identification of functionally variant MDR1 alleles among European–Americans and African–Americans. Clin. Pharmacol. Ther.70(2) , 189–199 (2001).
  • Tanabe M , IeiriI, NagataN et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther297(3) , 1137–1143 (2001).
  • Morita Y , SakaedaT, HorinouchiM et al.: MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm. Res.20(4) , 552–556 (2003).
  • Verstuyft C , SchwabM, SchaeffelerE et al.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol.58(12) , 809–12 (2003).
  • Marzolini C , PausE, BuclinT, KimRB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther75(1) , 13–33 (2004).
  • Llerena A , BereczR, DoradoP et al.: Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J. Chromatogr.B783 , 213–219 (2003).
  • Shi YY , HeL: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci.Cell Res.15(2) , 97–98 (2005).
  • Fanous AH , van den Oord EJ, Riley BP et al.: Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am. J. Psychiatry162(10) , 1824–1832 (2005).
  • Hitzl M , DrescherS, van der Kuip H et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics11(4) , 293–298 (2001).
  • Siegmund W , LudwigK, GiessmannT et al.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther.72(5) , 572–583 (2002).
  • Kimchi-Sarfaty C , GribarJJ, Gottesman MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol.62(1) , 1–6 (2002).
  • Morita N , YasumoriT, NakayamaK: Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities.Biochem. Pharmacol.65(11) , 1843–1152 (2003).
  • Sakaeda T , NakamuraT, HorinouchiM et al.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res.18(10) , 400–404 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.